Previous
Previous

Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform

Next
Next

Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs